CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A. Kriegsman and Vice ... read more

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of an international Phase 2b clinical trial to evaluate the preliminary ... read more

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that results from the open-label, single-agent Phase 2 ENABLE proof-of-concept clinical trial ... read more

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a ... read more

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors ... read more

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is tripling the number of patients in its Phase 1b/2 clinical trial who will ... read more

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that David Haen, the Company’s Vice President of Business Development, will present at the Rodman & Renshaw ... read more

CytRx Corporation (Nasdaq:CYTR) President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, MD, Ph.D., shared their views on potential advantages of the Company and its ... read more